论文部分内容阅读
目的观察匹多莫德联合头孢曲松治疗老年支气管肺炎的临床疗效。方法60例患者随机分为两组(各30例),治疗组在对照组治疗的基础上加用匹多莫德。比较两组治疗后的临床疗效,同时检测治疗前后免疫抗体、T细胞亚群的变化。结果治疗组与对照组的有效率分别为93.3%和70.0%,两者比较有显著性差异(P<0.01)。治疗组较治疗前IgA、IgG、T细胞亚群CD3+、CD4+均明显升高(p<0.01),CD8+明显下降(p<0.05)。对照组以上指标治疗前后无明显变化。结论治疗组疗效优于对照组,匹多莫德可通过增强免疫功能提高抗感染药物临床疗效。
Objective To observe the clinical efficacy of pidotimod combined with ceftriaxone in the treatment of bronchial pneumonia in the elderly. Methods Sixty patients were randomly divided into two groups (n = 30 each). The treatment group was given pidotimod on the basis of the treatment of the control group. The clinical efficacy of the two groups after treatment was compared, and the changes of immune antibody and T cell subsets before and after treatment were also measured. Results The effective rates of the treatment group and the control group were 93.3% and 70.0%, respectively, with significant difference (P <0.01). The levels of CD3 + and CD4 + of IgA, IgG and T cell subsets in treatment group were significantly increased (p <0.01) and CD8 + significantly decreased (p <0.05). There was no significant change in the control group before and after treatment. Conclusion The curative effect of the treatment group is better than that of the control group. Pidotimod can improve the clinical efficacy of anti-infective drugs by enhancing the immune function.